valproic acid has been researched along with Uremia in 13 studies
Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.
valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.
Uremia: A clinical syndrome associated with the retention of renal waste products or uremic toxins in the blood. It is usually the result of RENAL INSUFFICIENCY. Most uremic toxins are end products of protein or nitrogen CATABOLISM, such as UREA or CREATININE. Severe uremia can lead to multiple organ dysfunctions with a constellation of symptoms.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Limited studies indicate increased free fraction of valproic acid in uremia." | 3.69 | Reduced in vitro displacement of valproic acid from protein binding by salicylate in uremic sera compared with normal sera. Role of uremic compounds. ( Dasgupta, A; Jacques, M, 1994) |
| " Treatment of normal plasma with urea or creatinine to reproduce concentrations observed in uremia induced small decreases in binding." | 3.66 | Valproate plasma protein binding in the uremic condition. ( Brewster, D; Muir, NC, 1980) |
| "Phenytoin assays were evaluated using an additional set of samples from patients with abnormal renal function." | 1.31 | Performance characteristics of four immunoassays for antiepileptic drugs on the IMMULITE 2000 automated analyzer. ( Annesley, TM; Frank, EL; Juenke, J; Roberts, WL; Schwarz, EL, 2002) |
| "Ketoconazole is an antifungal agent widely used in the management of patients with fungal infection, especially in patients with acute acquired immuno-deficiency syndrome (AIDS)." | 1.30 | Valproic acid-ketoconazole interaction in normal, hypoalbuminemic, and uremic sera: lack of interaction in uremic serum caused by the presence of inhibitor. ( Dasgupta, A; Luke, M, 1997) |
| "Valproic acid is an anticonvulsant that is strongly bound to serum albumin." | 1.29 | Interaction of valproic acid with nonsteroidal antiinflammatory drugs mefenamic acid and fenoprofen in normal and uremic sera: lack of interaction in uremic sera due to the presence of endogenous factors. ( Dasgupta, A; Emerson, L, 1996) |
| " Serum level decline was biphasic in both instances with a terminal half-life of 27." | 1.27 | The effects of peritoneal dialysis on the single dose and steady state pharmacokinetics of valproic acid in a uremic epileptic child. ( Abbott, FS; Farrell, K; Ferguson, S; Godolphin, WJ; Orr, JM, 1983) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (23.08) | 18.7374 |
| 1990's | 5 (38.46) | 18.2507 |
| 2000's | 5 (38.46) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ohtsuki, S | 1 |
| Asaba, H | 1 |
| Takanaga, H | 1 |
| Deguchi, T | 1 |
| Hosoya, K | 1 |
| Otagiri, M | 1 |
| Terasaki, T | 1 |
| Frank, EL | 1 |
| Schwarz, EL | 1 |
| Juenke, J | 1 |
| Annesley, TM | 1 |
| Roberts, WL | 1 |
| Reiter, K | 1 |
| Bordoni, V | 1 |
| Dall'Olio, G | 1 |
| Ricatti, MG | 1 |
| Soli, M | 1 |
| Ruperti, S | 1 |
| Soffiati, G | 1 |
| Galloni, E | 1 |
| D'Intini, V | 1 |
| Bellomo, R | 1 |
| Ronco, C | 1 |
| Buka, R | 1 |
| Hille, R | 1 |
| McCormack, P | 1 |
| Orr, JM | 1 |
| Farrell, K | 1 |
| Abbott, FS | 1 |
| Ferguson, S | 1 |
| Godolphin, WJ | 1 |
| Bruni, J | 1 |
| Wang, LH | 1 |
| Marbury, TC | 1 |
| Lee, CS | 1 |
| Wilder, BJ | 1 |
| Brewster, D | 1 |
| Muir, NC | 1 |
| Dasgupta, A | 6 |
| Jacques, M | 2 |
| Volk, A | 1 |
| Malhotra, D | 1 |
| Emerson, L | 1 |
| Luke, M | 1 |
| Paul, A | 1 |
| Wells, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Cytokine Adsorption in Severe, Refractory Septic Shock[NCT04910893] | 48 participants (Actual) | Interventional | 2014-11-27 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
13 other studies available for valproic acid and Uremia
| Article | Year |
|---|---|
Role of blood-brain barrier organic anion transporter 3 (OAT3) in the efflux of indoxyl sulfate, a uremic toxin: its involvement in neurotransmitter metabolite clearance from the brain.
Topics: Animals; Antimetabolites; Biological Transport; Blood-Brain Barrier; Brain; Capillaries; Cells, Cult | 2002 |
Performance characteristics of four immunoassays for antiepileptic drugs on the IMMULITE 2000 automated analyzer.
Topics: Anticonvulsants; Carbamazepine; Chromatography, High Pressure Liquid; Cross Reactions; Drug Monitori | 2002 |
In vitro removal of therapeutic drugs with a novel adsorbent system.
Topics: Adsorption; Anti-Bacterial Agents; Biocompatible Materials; Carbamazepine; Digoxin; Glycopeptides; H | 2002 |
Yellow nail pigmentation following Depakote therapy.
Topics: Antimanic Agents; Bipolar Disorder; Female; Humans; Middle Aged; Nail Diseases; Pigmentation Disorde | 2003 |
The effects of peritoneal dialysis on the single dose and steady state pharmacokinetics of valproic acid in a uremic epileptic child.
Topics: Child; Epilepsy; Half-Life; Humans; Kinetics; Peritoneal Dialysis; Uremia; Valproic Acid | 1983 |
Protein binding of valproic acid in uremic patients.
Topics: Humans; Kidney Failure, Chronic; Protein Binding; Renal Dialysis; Uremia; Valproic Acid | 1980 |
Valproate plasma protein binding in the uremic condition.
Topics: Blood Proteins; Charcoal; Creatinine; Dialysis; Female; Humans; Hydrogen-Ion Concentration; Male; Pr | 1980 |
Reduced in vitro displacement of valproic acid from protein binding by salicylate in uremic sera compared with normal sera. Role of uremic compounds.
Topics: Charcoal; Drug Interactions; Humans; In Vitro Techniques; Protein Binding; Salicylates; Salicylic Ac | 1994 |
Displacement of valproic acid and carbamazepine from protein binding in normal and uremic sera by tolmetin, ibuprofen, and naproxen: presence of inhibitor in uremic serum that blocks valproic acid-naproxen interactions.
Topics: Binding, Competitive; Blood Proteins; Carbamazepine; Cyclooxygenase Inhibitors; Drug Interactions; H | 1996 |
Diminished protein binding capacity of uremic sera for valproate following hemodialysis: role of free fatty acids and uremic compounds.
Topics: Anticonvulsants; Charcoal; Creatinine; Fatty Acids, Nonesterified; Humans; In Vitro Techniques; Prot | 1996 |
Interaction of valproic acid with nonsteroidal antiinflammatory drugs mefenamic acid and fenoprofen in normal and uremic sera: lack of interaction in uremic sera due to the presence of endogenous factors.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticonvulsants; Drug Interactions; Fenoprofen; Humans; Mef | 1996 |
Valproic acid-ketoconazole interaction in normal, hypoalbuminemic, and uremic sera: lack of interaction in uremic serum caused by the presence of inhibitor.
Topics: Anticonvulsants; Antifungal Agents; Drug Interactions; Humans; Ketoconazole; Uremia; Valproic Acid | 1997 |
Uremic sera contain inhibitors that block digitoxin-valproic acid interaction.
Topics: Anticonvulsants; Binding Sites; Binding, Competitive; Cardiotonic Agents; Digitoxin; Drug Interactio | 2001 |